Dr. Neelapu on Third-Line CAR T-Cell Therapy in Large B-Cell Lymphoma

Video

In Partnership With:

Sattva Neelapu, MD, discusses the use of CAR T-cell therapy in the third-line setting for patients with large B-cell lymphoma.

Sattva Neelapu, MD, professor of lymphoma and myeloma at The University of Texas MD Anderson Cancer Center, discusses the use of CAR T-cell therapy in the third-line setting for patients with large B-cell lymphoma.

Axicabtagene ciloleucel (axi-cel; Yescarta) and tisagenlecleucel (Kymriah) are currently the only CAR T-cell products approved for patients with relapsed/refractory large B-cell lymphoma who have failed 2 or more lines of systemic therapy. This indication includes the histologies of diffuse large B-cell lymphoma and high-grade B-cell lymphoma, explains Neelapu.

Currently, these products are used in the third-line setting and beyond, typically after patients with B-cell lymphoma have failed the frontline chemotherapy and the second-line autologous stem cell transplantation. Previously, the outcomes of these patients had been pretty dismal with a median survival of 46 months, according to Neelapu. Updated 2-year data for axi-cel and tisagenlecleucel show durable responses, Neelapu says.

Related Videos
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD